Compare UK & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UK | NXTS |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Business Services | Agricultural Chemicals |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1M | 2.5M |
| IPO Year | 2020 | 2021 |
| Metric | UK | NXTS |
|---|---|---|
| Price | $1.95 | $1.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 22.9K | 17.2K |
| Earning Date | 03-24-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $263,445.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $0.55 |
| 52 Week High | $5.90 | $23.80 |
| Indicator | UK | NXTS |
|---|---|---|
| Relative Strength Index (RSI) | 47.44 | 38.96 |
| Support Level | $1.91 | $1.43 |
| Resistance Level | $2.27 | $2.08 |
| Average True Range (ATR) | 0.15 | 0.14 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 52.36 | 18.19 |
Ucommune International Ltd is a flexible office space provider and manager based in the People's Republic of China (PRC). The company offers long-term leasing, on-demand, and short-term leasing solutions to freelancers, start-up entrepreneurs, small and medium enterprises, and corporations. Company provide fully-serviced and well-furnished office spaces on a flexible basis. The members of the Ucommune community, which includes individuals and enterprises registered on the U bazaar mobile app, can avail of these services. The company has two operating segments: Workspace membership, and Other services. The Workspace membership segment generates the majority of the company's revenue.
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.